News

Ocrevus (ocrelizumab) is the first and only licensed treatment for people with early, inflammatory primary progressive multiple sclerosis in Ireland.

Dublin, 1st of October 2020 – Roche Products (Ireland) Ltd. (“Roche”), today, announced that OCREVUS® (ocrelizumab) is now publicly available in Ireland to treat people living with primary progressive multiple sclerosis (PPMS). More than 9,000 people in Ireland are living with MS(1) and it is estimated that PPMS, a highly disabling form of MS, and according to MS Ireland, affects approximately 15% of people diagnosed with MS(1).

Robert Joyce shares his opinion on what he would like to see the Government address in the upcoming budget.

Researchers at Trinity College Dublin and Beaumont Hospital are carrying out a study exploring cognitive changes (thinking and memory) in Multiple Sclerosis.

This week guest blogger Declan Groeger raises awareness of Make Way Day and accessibility.

Assistive Technology online workshops for people living with MS, their circle of support, family and friends.

'Among symptoms such as difficulties with cognition, decreasing mobility, fatigue, bowel and urinary issues- my symptoms are in all parts of my body- pain is always a major factor'

This week Mary Devereux shares with us her story of day to day living with MS and pain.

This week Robert Joyce shares his hopes for the 2020 MS READaTHON

This week Joan Jordan shares with us why she is involved in clinical trials, research and EUPATI